Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

NCT00646386 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis
Psoriatic

Interventions

DRUG: adalimumab
DRUG: placebo for adalimumab

Sponsor

Abbott